Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Nov 1;39(6):917–930. doi: 10.3904/kjim.2024.019

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 The Korean Association of Internal Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 6. — Treatment effect of TMSCs in chronic murine colitis model. (A) In the chronic colitis model, the macroscopic DAI scores were significantly lower in the TMSC-treated group compared to the DSS + PBS group (p < 0.001). (B) Body weight loss (%) in the TMSC-treated group was significantly lower than in the DSS + PBS group (-18.8 ± 25.1 vs. 7.6 ± 14.0, p < 0.001). (C) In the TMSC-treated group, DSS-induced colon shortening was significantly decreased compared to the DSS+PBS group (68.0 ± 3.4 vs. 81.5 ± 2.9, p = 0.0148). (D) The levels of pro-inflammatory cytokines, including IL-1β and IL-17, were significantly decreased in the TMSC-treated group compared with the colitis control group (p = 0.028 and p = 0.041, respectively). DSS, dextran sulfate sodium; PBS, phosphate-buffered saline; TMSC, tonsil-derived mesenchymal stem cell; DAI, disease activity index.